Inhaled nitric oxide allows selective pulmonary vasodilatation with rapidity of action. It is effective in the acute post-operative management of pulmonary hypertension in cardiac surgical patients and is also valuable in assessing the pulmonary vasodilator capacity in patients with chronic pulmonary hypertension. This review examines the current role of inhaled nitric oxide in cardiac medicine, discussing issues concerning its administration and toxicity, as well as a summary of clinical studies in cardiac patients. New roles, as a modifier of platelet and leukocyte function, post-thrombolysis and following lung transplantation are described. New agents and alternative therapies, which prolong pulmonary activity, are also discussed.
Introduction
pulmonary hypertension [4] . From these studies, it was recognised that pulmonary vasodilatation could be One of the most remarkable discoveries made in modern achieved by low concentrations of INO (5-80 ppm), medical science is that nitric oxide (NO), which has long without systemic haemodynamic effects. The first widebeen regarded as a toxic constituent of cigarette smoke and spread therapeutic role for NO was found in the manageenvironmental pollutant [1] , plays a critical role in a ment of persistent pulmonary hypertension of the newborn startling number of physiological processes. Examples [5, 6] . Since then, the role for INO has been further defined, include nitric oxide's role as a modulator of vascular tone, not only in pulmonary, but also in cardiac disorders. This platelet and leukocyte activation, its role as a neuroreview will focus on the role of INO in cardiac medicine; transmitter and as a mediator of immune and inflammatory its administration and pharmacology, a discussion of the responses. Its fundamental action within the blood vessel is haemodynamic consequences of INO (particularly with activation of soluble guanylate cyclase, catalysing formarespect to left and right ventricular function), as well as tion of cGMP from GTP [2] . Nitric oxide is a free radical non-haemodynamic uses of INO and recent developments that exists as an unstable gas at room temperature. A in alternatives and supplementary therapies to INO. therapeutic role for inhaled NO (INO) was first suggested in 1991 in a lamb model of hypoxic pulmonary hypertension [3] and in a series of post-surgical patients with
Background
Following inhalation, due to its small size and lack of muscle [13, 14] and myocardial cell [15] [16] [17] preparations. Nitric oxide has also been implicated in the cardiac dysfunction of cardiomyopathy [18] , cardiac allograft rejection [19, 20] and sepsis [13] . In addition, increased inducible NO synthase expression and activity has been reported in states of dilated cardiomyopathy and myocarditis [18] . In vivo studies have suggested that NO may be involved in the downregulation of b-receptor responsiveness in patients with heart failure [21] . While all these reports suggest a negative inotropic effect of NO, it has recently been found that NO may have concentrationdependent effects on contractility with positive inotropic effects at very low concentrations [22, 23] . As INO is typically used in haemodynamically unstable or critically ill patients, it is important to discern whether these experimental findings have clinical significance.
Pharmacology and toxicity

Delivery and monitoring of INO
Radiolabelling studies have shown that approximately 75% of the NO delivered by inhalation is absorbed [30, 31] . Because it is rapidly transformed into higher oxides of nitrogen (NO ) in the presence of oxygen, NO is usually oxyhaemoglobin, MetHb5MetHb, NO 5nitrite, NO 5nitrate. preferably with a mixing device in the inspiratory limb (to minimise peak gas concentrations) and synchronised invascular relaxation, and, while the possibility of bronspiratory injection, where available [33] . chodilatation also exists, it is not apparent in normal While the commonest method for monitoring NO consubjects [8] . Indeed, controversy exists as to whether INO centration delivered is the measurement of an electroimproves [8,9] or exacerbates [10] acute or chronic airflow chemical gradient induced by NO (with an accuracy of 1 limitation. Once in the vascular compartment, its activity is ppm), the gold standard remains chemoluminescence limited by rapid inactivation, particularly in the presence monitoring (accuracy of a few ppb) [33] . Expiratory of oxyhaemoglobin. The interaction between NO and monitoring or scavenging is not considered necessary, as haemoglobin was first described in sheep blood in the the effect of delivering NO on the ambient NO and NO x 1950s [11] and underlies the selectivity of its pulmonary concentrations is negligible [34] . As methaemoglobin action [12] .
(MetHb) is a by-product of the metabolism of INO (discussed subsequently), it has been recommended that 2.1. NO modulation of ventricular function serum MetHb measurements should be performed prior to, at 1 h, 6 h and daily following institution of INO [33] . Soon after discovery of its role in vascular modulation, NO was shown to also be important in modulating 3.2. Metabolism of INO myocardial function [13] . Many reports have suggested that NO has a negative inotropic effect in isolated papillary On arrival in the bloodstream, NO rapidly combines with the haem unit of haemoglobin and thiol groups of not be by spontaneous release, but via a catalytic reaction serum proteins [35, 36] . The affinity of NO for these at the level of the smooth muscle cell wall [45] before the latter is excreted, mostly in the urine [30, 40] . haemodynamic response (usually defined by a decrease in 15 Using radiolabelled NO ( NO), it has been shown that pulmonary vascular resistance) may be higher than those 15 2 nitrate ( NO ), accounts for at least 70% of the end required for an improvement in oxygenation [29] . Doses 3 product of INO in healthy individuals [43] . required for anti-platelet effect or inhibition of leukocyte It has been suggested that the formation of S-nitrosoadhesiveness, discussed later, may be even higher. adducts by interaction with serum thiol groups may provide an important intermediary pathway in the activity 3.4. Toxicity of INO of NO [35, 44] . The half-lives of nitrosothiols are much longer (15-30 s) than free NO [41] providing a theoretical Toxicity due to INO may be due both to the effects of mechanism for activity at sites outside the pulmonary NO itself or to its metabolites. Extreme concentrations of vasculature (Fig. 2) . Quantitatively, the largest NO adduct INO are associated with acute oxidation injury in the lung is S-nitroso-serum albumin, which accounts for approxiwith consequent inflammation, desquamation and interstimately 80% of all nitrosothiols [44] . It has been suggested tial oedema [47] . It has been suggested that some of the that the mechanism of NO activity due to nitrosothiols may damaging respiratory effects of cigarette smoke may be due to the high concentration of INO delivered (500 ppm) with consequent nitrosylation of proteins, production of peroxynitrites and depletion of antioxidants, interfering with fundamental enzyme and signalling systems [48] . Experimental and clinical studies have not revealed pulmonary histological abnormalities or evidence of oxidative damage due to continuous INO at therapeutic concentrations of 20-80 ppm, however [3, 41, 49] . In reports of the prolonged administration of INO (20 ppm for up to 53 days) in a group of patients with adult respiratory distress syndrome (ARDS) [50] , and for 68 days at a mean 50 ppm [51] no evidence of lung toxicity has been detected. Genetic studies have not shown any increase in aberrant peripheral blood lymphocytes, indicative of chromosome abnormalities, in response to short duration INO (2 h at 40 ppm) [52] . rates, these higher oxides may accumulate and themselves may be transient, and some investigators have suggested be associated with systemic hypotension. Adverse effects that a mild increase in pulmonary pressure need not of NO include depletion of antioxidants and lipid peroximandate continuing INO therapy if it is haemodynamically 2 dation at markedly lower concentrations (14 ppm) than are tolerated [57] . needed for NO toxicity [53] . While it has been recommended that inspiratory NO levels be maintained at 2 less than 1 ppm [54] , United Kingdom guidelines for the 4. Uses of INO in adult cardiology practice use of INO in intensive care accept a maximum inspiratory concentration of NO of up to 3 ppm [33] .
In adult cardiology practice, the main roles for INO are 2 A further toxic pathway relates to the metabolic byin the management of post-operative pulmonary hypertenproducts. While small increases in MetHb levels have been sion after cardiac surgery and in the assessment of acute documented [4], there have not been any reports of pulmonary vasodilator reserve in patients with isolated significant morbidity due to this alone. With brief cessation pulmonary hypertension. Other uses include the assessof INO, MetHb levels rapidly return to normal. During ment of acute pulmonary vasodilator reserve in patients continuous INO at 40 ppm, Jacob and colleagues found who are being assessed for heart transplantation and who that MetHb levels stabilised while serum nitrates gradually have pulmonary hypertension secondary to left ventricular climbed, consistent with MetHb being an intermediate in failure, and in the treatment of acute pulmonary hypertenthe NO metabolic pathway [41] . In a dose response study, sive crises in patients with pulmonary hypertension of any Young showed that at usual therapeutic doses of INO (32 cause. The commonest use for INO in adults in the United ppm) MetHb levels peaked at only 1%. Significant MetHb Kingdom is in the management of ventilated patients with (5% of total haemoglobin) could be induced within one h ARDS [33] , following early reports of benefit [50] . Subof inhalation with extreme concentrations of INO (512 sequent studies in similar patients have confirmed a minor ppm) [55] . Concentrations lower than this resulted in decrease in oxygen and ventilation requirements, but no plateauing of the MetHb concentration curves, suggesting improvement in mortality [64, 65] . that NADH MetHb reductase activity was not saturated at those levels in normal, healthy volunteers. Similar levels of 4.1. Use of INO in post-operative cardiac patients MetHb have been obtained in patients with cardiac failure, following short inhalations, to a maximum of approximate-4.1.1. Post coronary artery bypass grafting ly 2% at 80 ppm [24] .
Inhaled NO, at concentrations of 20 and 40 ppm, has An indirect adverse effect of NO is associated with its been shown to be effective in decreasing pulmonary short duration of action. It has been reported on numerous pressures in a number of studies following coronary artery occasions that abrupt cessation of delivery may be associbypass grafting (CABG), even in subjects without marked ated with deleterious increases in pulmonary pressures and pre-existing pulmonary hypertension [26, 66, 67] . This is right ventricular decompensation [29, [56] [57] [58] . This may be itself significant, in that subjects with normal pulmonary inadvertent and corrected by recommencement of delivery resistance do not usually respond to INO. These results [54, 58] , but further emphasises continuous monitoring of suggest that there is a degree of reversible pulmonary inhaled concentrations. One of the mechanisms postulated hypertension, due to pulmonary endothelial dysfunction to account for this is suppression of the endogenous NO (discussed subsequently), or possibly increased levels of pathway in the pulmonary vasculature [59] . This has been circulating cytokines associated with cardiopulmonary shown to be true for bovine aortic endothelial cells bypass [68] . Not all studies have demonstrated a benefit exposed to NO and NO donors [60] and is further post CABG, however. In one surgical series, it was found supported by experimental studies of chronic hypoxia that only those subjects undergoing cardiac surgery for a combined with prolonged (3 week) INO administration mitral valvular problem responded significantly to INO, which have shown impairment in pulmonary endothelial not those undergoing CABG [69] . The differences in mean function [61] . Studies have generally shown that protein pulmonary artery pressures between these studies was not and transcription levels of NO synthase (NOS) are unafmarked (29(1 mmHg [26] ; 20(1 mmHg in [66] ; median of fected [62] , but both guanylate cyclase and NOS activity 17 mmHg (range 12-24 mmHg) [69] ), but still may have may be decreased by NO [62, 63] . Suggested mechanisms had a role in explaining the different results. Previous for this negative feedback include conformational changes studies in patients undergoing cardiopulmonary bypass of NOS due to NO binding [60] , or peroxynitrite formation have shown that the degree of decrease in PVR due to INO directly inhibiting NOS activity [63] . Whatever the mechais proportional to the pre-operative PVR [70] . nism of the rebound increase in pulmonary vascular
The evidence for pulmonary endothelial abnormality resistance (PVR) following cessation of INO, it has been associated with cardiopulmonary bypass is convincing. recommended, for ventilated patients, that a back-up Wessel has shown that, in children undergoing repair of system be available [33] . With respect to weaning of INO, acyanotic congenital heart defects, whereas acetylcholine it is worth noting that the rebound haemodynamic changes (ACh) induced significant pulmonary vasodilatation pre-operatively, the same dose was much less effective postand INO, Kieler-Jensen found that intravenous prosbypass [71] . Pulmonary vasodilatation was still able to be tacyclin was the most potent in increasing (LV) cardiac achieved using INO, suggesting pulmonary endothelial index post transplantation, but that INO remained the only defect. Furthermore, cGMP levels following ACh were not selective pulmonary vasodilator [83] . The PVR achieved increased post-bypass, but again were increased following by prostacyclin and INO were similar. It has been sug-INO, suggesting normal vascular smooth muscle productgested that therapeutic response times were longer in the ion capability. In a further series of 30 children, Beghetti transplanted patient, possibly due to histological or strucdocumented a 75% decrease in exhaled nitric oxide tural changes in the lung [81] . following cardiopulmonary bypass [72] . This occurred despite a post-operative decrease in haemoglobin, which 4.1.4. Post insertion of left ventricular assist device has previously been associated with increased exhaled NO.
After insertion of left ventricular assist devices (LVAD), The possibility of increased NO metabolism is not expulmonary hypertension and right heart failure is associcluded by this study, but in light of other evidence, it ated with inadequate LVAD filling and decreased survival. appears likely that pulmonary endothelial dysfunction is
In one early series, over 20% of patients developed right the major cause.
heart failure or required a right ventricular assistance following LVAD implantation [84] . Inhaled NO has been 4.1.2. Pulmonary hypertension associated with repair of used successfully in these situations to decrease pulmonary congenital and valvular heart disease pressures and support the right ventricle until cardiac Because congenital heart disease is itself associated with outputs are equilibrated or transplantation performed pulmonary hypertension, and may be associated with [85, 86] . For this reason, INO has been recommended prior pulmonary hypertensive crises immediately following corto consideration of implantation of an adjunctive right rective surgery, selective pulmonary vasodilatation has ventricular assist device, as this may be able to be avoided been shown to be beneficial, in infants [73, 74] , and if there is a good response to INO [87] . Such haemochildren [75, 76] .
dynamic benefits have been confirmed in a small randomIn adults, mitral valvular disease is also frequently ised trial, supporting this use [88] . associated with pulmonary hypertension. In a trial of only 10 min INO (37 ppm), Girard showed a 22% improvement 4.2. Use of INO in patients with congestive cardiac in PVR immediately post-operatively in a series of 6 failure patients undergoing mitral valve replacement for mitral stenosis [77] . In a mixed series of surgical patients Inhaled NO is frequently used in patients with conges-(predominantly mitral valvular disease), Rich showed a tive cardiac failure as part of their evaluation for cardiac 35% decrease in PVR, which was dependent on the transplantation [79] . As fixed pulmonary hypertension has baseline PVR [70] . In a series of 9 patients undergoing been associated with increased morbidity and mortality mitral valve surgery with only mild resting elevation in immediately post transplantation [89] , an assessment as to 25 PVR (median 274 dynes.s.cm ), Snow found that INO whether this can be corrected by vasodilators is required. reduced post-operative pulmonary vascular resistance, by Concern has been aroused, however, by a number of 42% [69] . These studies are contrasted with a further study patients with stable congestive cardiac failure developing by Fullerton who found that in adult patients undergoing documented pulmonary oedema during administration of valvular surgery, no benefit of INO was seen [78] . The INO [90] . Furthermore, a consistent haemodynamic finding difference between these studies is likely to be related to in patients with severe heart failure is not a decrease in the greater severity of the pulmonary hypertension in the mean pulmonary artery pressure, but an increase in mean 25 latter group (mean PVR 622 dynes.s.cm ). The vascular pulmonary capillary wedge pressure or LV end-diastolic remodelling involved in these patients most likely involved pressure during administration of INO [24, 25, 91, 92] . a degree of fibrosis limiting any reversibility. Similar These clinical observations, in combination with the in results are seen in cases of long-standing pulmonary vitro experimental evidence of a direct negative inotropic hypertension due to other causes [79, 80] .
action of NO [13, [15] [16] [17] has led to concern that INO may exert a clinically important negative inotropic effect in 4.1.3. Post cardiac transplantation patients whose ventricular function is already impaired. Because of immediate morbidity and mortality due to pulmonary hypertension following cardiac transplantation, 4.3. Left ventricular effects of INO INO has a particular role to play [81, 82] . The donor heart has to adapt to a new haemodynamic state, during which
In one study of patients with normal LV function, a time the PVR may need to be modulated selectively. As negative inotropic effect of INO was suggested due to lack with other conditions, traditional vasodilator therapy often of increase in cardiac output despite a significant decrease is associated with significant systemic hypotension limiting in RV afterload [26] . We have also found a decrease in use [54] . In a study comparing conventional vasodilators cardiac output in occasional patients with heart failure during administration of INO, despite the appropriate significantly impaired [25, 99] . By decreasing PVR in these decrease in pulmonary resistance (reported in part [25] ).
patients, the failing LV is subjected to an excessive volume While INO is inactivated rapidly in the presence of load with which it may not be able to cope. haemoglobin, the combination of NO with thiol groups on haemoglobin and plasma proteins to form active nitro-4.4. Use of INO in pulmonary hypertension sothiol adducts with longer half-lives [44] , discussed earlier, makes it possible that INO could exert effects at While INO has been shown to be of benefit in reducing more distal vascular beds such as the coronary circulation.
the PVR of acute pulmonary hypertension, independent of In view of the experimental evidence for a negative cause [3, 100] , its effects in patients with chronic PHT are inotropic effect of NO [13] [14] [15] [16] [17] , and the possibility of less predictable. Although some patients with chronic PHT action beyond the pulmonary circulation via nitrosothiols, do show an acute vasodilator response to INO, others do it was proposed that INO might be having an adverse not [80, 101, 102] . This most likely relates to the relative effect on LV function. A number of studies have subdegree of medial hypertrophy versus intimal hyperplasia sequently been performed to address this very issue.
and luminal thrombosis that occurs in the small pulmonary Because analysis of ventricular function in response to arteries in chronic lung vascular disease [80] . Because of pharmacological agents is frequently complicated by its potency and rapid onset of action, INO has been changes in loading conditions, we and others have used suggested as a screening tool for defining which patients simultaneous pressure-volume relations to assess the with pulmonary hypertension may benefit from long term effect of INO [93] [94] [95] [96] . In a population with normal LV oral vasodilating therapy, such as calcium antagonism function, we found no effect of INO on indices of left [101, 102] . In these studies which used invasive haemoventricular performance [94] . Previously documented dynamic monitoring, there was a strong correlation bechanges in LV preload were therefore attributed to changes tween response to INO and subsequent response to oral in ventricular loading, and not indicative of a negative therapy. Because only 30-40% of the subjects respond to inotropic effect for INO. Indeed, modelling studies have INO [101] [102] [103] , this finding represents a significant step suggested that an increase in LV preload can be predicted if forward in directed therapy. An attempt to assess the the baseline pulmonary volumes are already elevated and response to INO using a 6-min walk as a non-invasive the PVR decreases significantly in response to INO, marker of reversibility of pulmonary hypertension was not independent of any change in inotropic status of the model successful in a small clinical trial [104] . In that study of 6 ventricle [97] . The reason that such changes are seen in patients, there was no significant difference in distance severe congestive cardiac failure is because of the elevated walked or symptoms experienced during INO compared to pulmonary volumes at rest. The lack of negative inotropy placebo. Occasional patients with PHT who do have a due to INO has been confirmed in animal models of heart vasodilator response have been 'bridged' to transplantation failure and pulmonary hypertension [96] as well as in a with INO for as long as 68 days [51] . Inhaled NO may also human population [93] . Consistent with these results, is a have a role in 'bridging' patients with a degree of fixed further study by Hare and co-workers in subjects with pulmonary hypertension during periods of acute pulmonary cardiac failure dependent on mechanical left ventricular decompensation. assistance [98] . Using an LVAD to assist cardiac output both on and off INO, it was found that INO increased left 4.4. Right ventricular effects of INO ventricular filling pressures only when cardiac output was not assisted. During cardiac assistance there was no Because of the haemodynamic separation of the right increase in left atrial pressure. Despite the in vitro eviventricle from site of delivery of INO, any effects are dence, therefore, these in vivo studies are consistent in indirect. As PVR is the main determinant of right ventricusuggesting that an increase in pulmonary venous pressure lar afterload, the ventricle is very sensitive to any changes. only occurs when the ventricle is unable to respond to A number of studies have suggested that right ventricular increased preload by increasing output, rather than the efficiency is improved in response to INO, mainly as a increased preload occurring as an expression of negative result of decreasing pulmonary input impedance rather inotropy due to INO. than any change in right ventricular contractility [105, 106] . It has been suggested that the pulmonary hypertension One study, examining RV function in response to INO in associated with cardiac failure is not merely accumulation experimental pulmonary hypertension, found improved RV or 'backpressure' due to poor left ventricular output, but a dP/ dt during INO [107] , though this is a load-dependent reflex vasoconstriction, possibly to reduce left ventricular measure and not well suited to comparisons made across preload and protect the lungs from pulmonary congestion, differing volume and afterload states. The importance of at the cost of increased right ventricular work [91] . It this distinction is shown in a further study, which induced remains important to note, however, that even in the severe pulmonary hypertension, by microbead injections. absence of any inotropic effect, massive pulmonary vasoThe increase in PVR was itself associated with an increase dilatation may occasionally overwhelm the LV if it is in RV dP/ dt, which was partially normalised (decreased)
by INO [100] . Stroke volume decreased due to increased endothelium, occluding the coronary artery, delivering PVR and again was partially restored by INO, consistent thrombus and then administering thrombolysis to restore with improved haemodynamics, and independent of conpatency was used to generate a platelet rich thrombus. tractility changes.
While there was no effect of INO on measures of coronary Human studies involving impaired RV function in flow, the fraction of time that the artery was open was association with pulmonary hypertension have also sugincreased by both 20 and 80 ppm INO. Other indices of gested benefit from INO [108] . In a study of 14 patients anti-platelet activity were a decrease in the cyclic flow with severe congestive cardiac failure, Koelling found that variations that have been associated with intermittent those subjects with the most impaired right ventricular platelet deposition in similar models of thrombolysis. function responded best to INO in improving their exercise Despite the short half-life of INO, the anti-platelet effect capacity [109] . From this, it was suggested that the lasted for at least 45 min after cessation of the 80 ppm pulmonary hypertension associated with the heart failure INO. In this study, a higher concentration of INO (200 was limiting right ventricular output and contributing to ppm) was not associated with any benefit. Inhaled NO, at their exercise intolerance [109] . A study of seven subjects concentrations of 200 and 400 ppm, did inhibit in vitro with congestive cardiac failure performing upright bicycle ADP-induced aggregation, but in vivo bleeding times were exercise, also showed improved oxygenation and maximal not affected. The lack of effect at the higher concentration oxygen uptake in response to INO associated with an of INO (200 ppm) may have been related to excess improved exercise tolerance [110] . The results in this latter formation of peroxynitrite at the higher concentration, study were explained on the basis of improvement in which may have a pro-aggregatory effect on platelets ventilation perfusion matching. This is consistent with under certain conditions [122] . The anti-platelet effects of redistribution of pulmonary blood flow to better ventilated INO remain minor compared to aspirin [115] , and it cannot areas in response to INO, as has been shown in a study be recommended as an alternative in this setting. using scintigraphy in patients with severe cardiac failure
The possibility that INO could have long-lasting physio- [111] . A recent study found that the improvement in logic or even structural effects is suggested by an exventilation / perfusion matching may be associated with perimental model of restenosis following balloon carotid improvement in arterial oxygenation in a group of patients injury in rats [123] . In that study, rats given 80 ppm INO with Class II-III congestive cardiac failure [112] .
for 1 or 2 weeks starting 1 h prior to injury were found to have lower intima / media ratios compared to those breath-4.5. Anti-platelet effects of INO ing air alone. These results were not reproduced if only 1 week of INO was given followed by air for 1 week or if Anti-platelet effects due to NO activation of soluble the rats were given a lower dose, 20 ppm, for 2 weeks. The guanylate cyclase in the platelet cytosol have been recogability of INO to block collagen induced in situ platelet nised for a number of years [113] . It has since been activation in rats has also been shown by Nong and recognised that this activity is evident even with inhalation colleagues at concentrations of 40 ppm or greater [124] . In [114] . The main effects of INO on platelet function have that study, the degree to which platelet aggregation could been seen as an increase in bleeding time, with little effect be blocked was closely associated with the intraplatelet on laboratory indices of platelet function in healthy cGMP levels, confirming activation of guanylate cyclase as subjects [115] or neonates [116] . In vitro studies have the likely mechanism of action. A possible mechanism for shown a dose-dependent inhibition of platelet aggregation, persisting effect, despite only relatively short periods of P-selectin expression and fibrinogen-glycoprotein IIb / IIIa inhalation, may be that INO may acutely alter platelet binding [117] . That study used dose ranges from 100-884 function blocking release of mitogens involved in migrappm, but similar results have also been obtained in patients tion of cells into the intima. This effect may be particularly with ARDS while receiving INO [118] . No increase in important in diseased coronary arteries related to impaired bleeding time was seen in the latter study. A therapeutic release of NO in patients with coronary atheroma [125] . It role for INO in limiting platelet deposition and activation is of note that the concentrations required for platelet in massive pulmonary embolism has recently been sugeffects are greater than those required for haemodynamic gested [119] . By both inhibiting platelet activation and benefit. This may be understood in light of the inactivation decreasing pulmonary resistance, INO may have dual of NO by haemoglobin as it traverses the bloodstream activity in this setting. Increased use of INO may introduce prior to interaction with platelets. adverse reactions in unexpected situations. Two cases of increased bleeding in patients undergoing chemotherapy 4.6. Effect of INO on leukocyte adhesion who required ventilation and INO therapy have been reported [120] .
While NO is involved in the mediation of the inIn a canine model of thrombolysis, Adrie and co-workflammatory response and massive release is associated ers found that INO increased coronary patency post with the hypotension and negative inotropy of sepsis [2], it thrombolysis [121] . In this model, denuding an area of has also been shown that inhibition of NO actually increases neutrophil-endothelial cell interaction [126] . A studies are obviously needed if these statements are indeed subsequent study has shown that the increase in leukocyte borne out. adhesion with L-NAME can be abolished by INO [127] . In that study, inhaled NO had no effect on leukocyte adhesion in the absence of NO depletion, nor in states of NO excess, 6. Conclusions induced by endotoxaemia. These results suggest that INO may be helpful in replenishing NO activity in states of Despite concerns over possible toxicity, INO has been pulmonary endothelial deficit. This mechanism may be shown to be safe when closely monitored and has signifiimportant in explaining the benefit of INO in acute cant advantages as a selective pulmonary vasodilator. It reperfusion injury seen in transplanted lungs [128] . Such has a particular role in post-operative management of lungs have been shown to have depleted endothelial pulmonary hypertension in cardiac surgical patients and function [129] as well as dense polymorph infiltration.
the assessment of pulmonary vasodilator capacity, not only Murakami showed that INO (80 ppm) given during the in assessment prior to cardiac transplantation, but also in period of warm ischaemia and during reperfusion followplanning therapy for other forms of pulmonary hypertening lung transplantation from non-heart-beating donors was sion. While INO is rapidly inactivated by haemoglobin, the associated with a marked improvement, not only in lung possibility exists for nitrosothiol production, which may be function, but also a significant decrease in myeloperoxidan important intermediary in INO effect. New roles, ase activity [130] . Inhaled NO maybe particularly benefiincluding modifying both platelet and leukocyte function, cial in this setting, as it replenishes the pulmonary endooffer benefits after lung transplantation and possibly postthelial NO deficit thereby reducing PVR through vasodilatthrombolysis. New agents show promise in maintaining ation, as well as limiting the infiltration and subsequent pulmonary selectivity as well as an increased duration of activation of inflammatory cells. Again, the higher conaction. centration of INO required for inhibition of leukocyte adhesion compared to haemodynamic effects most likely relates to inactivation of NO in transit.
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